In the RADIOLA study, the RAD51-foci score is investigated if it has a predictive value on Olaparib efficacy in g/sBRCA or PALB2 or RAD51C/D mutation carrier advanced breast cancer patients; no results were posted [102]. This evidence concerns the gene RAD51 and breast carcinoma.